Loading...
MRNS logo

Marinus Pharmaceuticals, Inc.NasdaqGM:MRNS Stok Raporu

Piyasa Değeri US$30.3m
Hisse Fiyatı
n/a
1Y-94.6%
7D0.5%
1D0.2%
Portföy Değeri
​
Görünüm

Marinus Pharmaceuticals, Inc.

NasdaqGM:MRNS Stok Raporu

Piyasa değeri: US$30.3m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Marinus Pharmaceuticals (MRNS) Hisse Özeti

Bir ilaç şirketi olan Marinus Pharmaceuticals, Inc. nadir görülen genetik epilepsiler ve diğer nöbet bozukluklarından muzdarip hastalar için terapötik ürünlerin geliştirilmesi ve ticarileştirilmesine odaklanmaktadır. Daha fazla detay

Ödüller

Adil değer tahminimizden 92.6% daha düşük bir oranda işlem görüyor

Kazançların yılda 66.19% oranında artması öngörülüyor

Risk Analizi

Negatif hissedar öz sermayesi

Anlamlı bir piyasa değeri yok ( $30M )

1 yıldan az nakit akışı var

Son 3 ayda US piyasasına kıyasla dalgalı hisse senedi fiyatı


MRNS Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW440,641 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.
Grow your followingReal investors. The kind who actually invest, not scroll past.
Unlock free accessFree premium subscription for consistent and quality authors.
Learn moreCreate Narrative
B
BlackGoat
R
RockeTeller
I
Investingwilly
D
davidlsander
440,641 investors already sharing narratives
View all narratives

Marinus Pharmaceuticals, Inc. Rakipler

Fiyat Geçmişi ve Performans

Hisse fiyatlarındaki yükseliş, düşüş ve değişimlerin özeti Marinus Pharmaceuticals
Tarihsel hisse senedi fiyatları
Güncel Hisse FiyatıUS$0.55
52 Haftanın En Yüksek SeviyesiUS$10.50
52 Haftanın En Düşük SeviyesiUS$0.22
Beta1.03
1 Aylık Değişim2.33%
3 Aylık Değişim59.32%
1 Yıllık Değişim-94.62%
3 Yıllık Değişim-95.12%
5 Yıllık Değişim-94.03%
Halka arzdan bu yana değişim-98.28%

Son Haberler & Güncellemeler

Analiz Makalesi • Sep 20

A Piece Of The Puzzle Missing From Marinus Pharmaceuticals, Inc.'s (NASDAQ:MRNS) Share Price

It's not a stretch to say that Marinus Pharmaceuticals, Inc.'s ( NASDAQ:MRNS ) price-to-sales (or "P/S") ratio of 2.9x...
Analiz Makalesi • Aug 16

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Marinus Pharmaceuticals, Inc. ( NASDAQ:MRNS ) missed earnings with its latest quarterly results, disappointing...

Recent updates

Analiz Makalesi • Sep 20

A Piece Of The Puzzle Missing From Marinus Pharmaceuticals, Inc.'s (NASDAQ:MRNS) Share Price

It's not a stretch to say that Marinus Pharmaceuticals, Inc.'s ( NASDAQ:MRNS ) price-to-sales (or "P/S") ratio of 2.9x...
Analiz Makalesi • Aug 16

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Marinus Pharmaceuticals, Inc. ( NASDAQ:MRNS ) missed earnings with its latest quarterly results, disappointing...
Analiz Makalesi • May 11

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Just Reported, And Analysts Assigned A US$8.00 Price Target

Marinus Pharmaceuticals, Inc. ( NASDAQ:MRNS ) just released its latest first-quarter report and things are not looking...
Analiz Makalesi • Apr 16

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Might Not Be As Mispriced As It Looks After Plunging 86%

The Marinus Pharmaceuticals, Inc. ( NASDAQ:MRNS ) share price has fared very poorly over the last month, falling by a...
Analiz Makalesi • Mar 08

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Analysts Are Cutting Their Estimates: Here's What You Need To Know

Marinus Pharmaceuticals, Inc. ( NASDAQ:MRNS ) missed earnings with its latest annual results, disappointing...
Analiz Makalesi • Dec 22

Does Marinus Pharmaceuticals (NASDAQ:MRNS) Have A Healthy Balance Sheet?

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Analiz Makalesi • Sep 22

Is Marinus Pharmaceuticals (NASDAQ:MRNS) Using Debt Sensibly?

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Analiz Makalesi • Jun 12

Why Investors Shouldn't Be Surprised By Marinus Pharmaceuticals, Inc.'s (NASDAQ:MRNS) P/S

When close to half the companies in the Pharmaceuticals industry in the United States have price-to-sales ratios (or...
Analiz Makalesi • May 16

Forecast: Analysts Think Marinus Pharmaceuticals, Inc.'s (NASDAQ:MRNS) Business Prospects Have Improved Drastically

Shareholders in Marinus Pharmaceuticals, Inc. ( NASDAQ:MRNS ) may be thrilled to learn that the analysts have just...
Analiz Makalesi • Oct 26

Analysts Just Made A Major Revision To Their Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Revenue Forecasts

One thing we could say about the analysts on Marinus Pharmaceuticals, Inc. ( NASDAQ:MRNS ) - they aren't optimistic...
Analiz Makalesi • Oct 12

Is Marinus Pharmaceuticals (NASDAQ:MRNS) Weighed On By Its Debt Load?

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Seeking Alpha • Sep 22

Marinus Pharmaceuticals: Positive News Flow Of Note

Summary Today, we put Marinus Pharmaceuticals back in the spotlight as the stock has held up well even as the market has sold off. The company also has seen some positive news flow of late including the sale of a priority review voucher and some additional cash flow from BARDA. An investment analysis follows in the paragraphs below. Humility means accepting reality with no attempt to outsmart it.”― David Richo When we last revisited Marinus Pharmaceuticals, Inc. (MRNS) in May, we recommended it for a small covered call position. That seems to have been a prudent call to this point as the stock is basically trading flat/slightly up to when we last looked at it. Given how poorly biotech stocks have traded in 2022, that marks a victory. Seeking Alpha We are circling back today to update the investment thesis around Marinus as the company has seen some positive news flow in recent weeks. An analysis follows below. Company Overview: Marinus Pharmaceuticals is focused on the development of therapies for the treatment of rare genetic epilepsies and other seizure disorders. The company is based outside of Philadelphia, PA. The stock trades for around $6.50 a share and sports an approximate market capitalization of $260 million. May Company Presentation The company has one primary asset under development for multiple indications called ganaxolone. This compound is also known by its brand name Ztalmy was approved this March for seizures associated with cyclin-dependent-kinase like 5 (CDKL5) deficiency disorder (CDD). The marketing application for Ztalmy in Europe is currently undergoing review by the European Medicines Agency or EMA. The company plans to submit complete responses to questions from the EMA in November and they should render a decision in the first quarter of next year. May Company Presentation Recent Developments for Marinus: The priority review voucher Marinus garnered via the approval of Ztalmy by the FDA was sold at the end of August for $110 million. This bolstered the company's cash reserves substantially and was right in the range ($100 million to $125 million) these vouchers have received in recent years. In addition, it was announced that Biomedical Advanced Research and Development Authority or BARDA had exercised its first contract option worth ~$12.3M, to support U.S. onshoring of manufacturing capabilities of Ztalmy. That still leaves some $39 million of potential awards under this contract, $21 million in previously approved base-period funding and up to $18 million across two additional option periods. Company Website The company continues to advance ganaxolone against other indications. Marinus has a Phase 3 trial "RAISE" to evaluate ganaxolone to treat Refractory Status Epilepticus or RSE. Topline results from this study should be out in the second half of 2023. This study is being funded by BARDA. May Company Presentation Recently the first patient was randomized and dosed in a Phase 3 trial to evaluate ganaxolone to treat Tuberous Sclerosis Complex or TSC. The study will consist of approximately targeting 80 clinical sites and topline results are not expected until the first quarter of 2024 at the earliest. May Company Presentation Results from a Phase 2 study around RSE was published in June and a Phase 3 study for RSE 'RAISE II' (for European registration) is expected to begin enrollment in the second half of 2023. May Company Presentation A Phase 2 trial 'RESET' evaluating ganaxolone in established status epilepticus on track to begin U.S. enrollment in the second half of this year. A Phase 2 trial to evaluate ganaloxone to treat Lennox-Gastaut syndrome is now targeted to begin in 2023. Analyst Commentary & Balance Sheet: The analyst community also seems to be turning more sanguine on Marinus' story. Over the past five weeks, four analyst firms including Robert W. Baird and JMP Securities have reissued Buy ratings on MRNS. Price targets proffered range from $17 to $32 a share. Approximately five percent of the outstanding float is currently held short. There has been no insider activity in this equity since March of 2021. The company ended the second quarter of this year with just over $90 million in cash and marketable securities on its balance sheet after posting a net loss of $39.4 million in the quarter. With the receipts from the priority review voucher in hand, management believes current funding levels are sufficient to fund it into the fourth quarter of 2023. Marinus has approximately $70 million of long term debt. Verdict: There are a wide range of sales and earnings estimates from the analyst community at the present time. Right now they expect the company to lose just over two bucks a share in FY2022 and over $3.50 a share in FY2023 as the company spends big on the rollout of Ztalmy and advancing its pipeline. Revenue estimates range from approximately $15 million to $60 million next fiscal year. The company had just $1.8 million worth of revenue in the second quarter.
Seeking Alpha • Aug 29

Marinus Pharma closes on sale of a U.S. FDA priority review voucher for $110M

Marinus Pharmaceuticals (NASDAQ:MRNS) on Monday said it had closed on the sale of a U.S. FDA voucher for $110M. The voucher, called the Rare Pediatric Disease Priority Review Voucher, entitles MRNS to a priority review from the agency and proceeds to carry out its drug development activities with an aim to treat rare pediatric diseases. MRNS said it had received the $110M of gross funds, which are in addition to the $92.3M the had reported in cash and cash equivalents as of June 30. The company said it would use the proceeds from the closing of the sale on the voucher for the commercial launch of seizure treatment Ztalmy, execution of its phase 3 clinical programs and other general expenditures. With the addition of this funding, MRNS said it now expects to fund its expenses and requirements and maintain the minimum cash balance required under its debt facility into Q4 2023. MRNS stock +4.2% to $6.97 after hours.
Analiz Makalesi • Aug 13

Analysts' Revenue Estimates For Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Are Surging Higher

Marinus Pharmaceuticals, Inc. ( NASDAQ:MRNS ) shareholders will have a reason to smile today, with the analysts making...
Seeking Alpha • Aug 10

Marinus Pharmaceuticals Q2 2022 Earnings Preview

Marinus Pharmaceuticals (NASDAQ:MRNS) is scheduled to announce Q2 earnings results on Thursday, August 11th, before market open. The consensus EPS Estimate is -$0.93 (-43.1% Y/Y) and the consensus Revenue Estimate is $2.31M (+20.9% Y/Y). Over the last 3 months, EPS estimates have seen 1 upward revision and 1 downward. Revenue estimates have seen 0 upward revisions and 3 downward.
Seeking Alpha • Jul 28

Marinus Pharma announces U.S. commercial launch of seizure therapy Ztalmy

Marinus Pharmaceuticals (NASDAQ:MRNS) on Thursday announced the U.S. commercial launch of Ztalmy for the treatment of seizures associated with CDKL5 deficiency disorder (CDD) in patients aged two years and older. CDD is a genetic disorder caused due to mutations in the CDKL5 gene. It is characterized by seizures, developmental delay and intellectual disability. Ztalmy, which is an oral treatment, got U.S. FDA approval earlier this year in March. Marinus (MRNS) also said it had established a patient support program called Ztalmy One which facilitates access to the treatment, including prescription benefits and financial support for patients with no insurance.
Seeking Alpha • May 05

Revisiting Marinus Pharmaceuticals

Today, we put biopharma concern Marinus Pharmaceuticals back in the spotlight for the first time in more than a year. Despite the fall in the stock recently, analyst firms remain strongly positive on the shares. An updated investment analysis follows in the paragraphs below.

Hissedar Getirileri

MRNSUS PharmaceuticalsUS Pazar
7D0.5%-3.4%-0.9%
1Y-94.6%44.7%14.2%

Getiri vs. Endüstri: MRNS geçen yıl % 44.7 oranında getiri sağlayan US Pharmaceuticals sektörünün gerisinde kaldı.

Getiri vs Piyasa: MRNS geçen yıl % 14.2 oranında getiri sağlayan US Piyasasının altında performans gösterdi.

Fiyat Oynaklığı

Is MRNS's price volatile compared to industry and market?
MRNS volatility
MRNS Average Weekly Movement16.3%
Pharmaceuticals Industry Average Movement8.6%
Market Average Movement6.9%
10% most volatile stocks in US Market15.3%
10% least volatile stocks in US Market2.9%

İstikrarlı Hisse Senedi Fiyatı: MRNS hisse senedi fiyatı, son 3 ayda US piyasasına kıyasla dalgalı seyretti.

Zaman İçindeki Volatilite: MRNS 'nin haftalık oynaklığı son bir yılda 21% dan 16% a düştü, ancak hâlâ US hisselerinin %75'inden yüksek.

Şirket Hakkında

KurulduÇalışanlarCEOWeb sitesi
2003166Scott Braunsteinmarinuspharma.com

Bir ilaç şirketi olan Marinus Pharmaceuticals, Inc. nadir genetik epilepsiler ve diğer nöbet bozukluklarından muzdarip hastalar için terapötik ürünlerin geliştirilmesi ve ticarileştirilmesine odaklanmaktadır. Sikline bağımlı kinaz benzeri 5 eksikliği bozukluğu ile ilişkili nöbetlerin tedavisi için akut ve kronik bakımda, yatarak ve kendi kendine tedavi ortamlarında yetişkin ve pediatrik hasta popülasyonları için oral bir süspansiyon olan ZTALMY (ganaxolone) sunmaktadır. Şirketin ZTALMY ürün adayı, anti-nöbet, antidepresan ve anksiyolitik potansiyeli için bir hedef olan sinaptik ve ekstrasinaptik GABAA reseptörlerinde etki gösterir.

Marinus Pharmaceuticals, Inc. Temel Bilgiler Özeti

Marinus Pharmaceuticals'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
MRNS temel i̇stati̇sti̇kler
Piyasa değeriUS$30.32m
Kazançlar(TTM)-US$140.49m
Gelir(TTM)US$31.47m
1.0x
P/S Oranı
-0.2x
F/K Oranı

MRNS aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
MRNS gelir tablosu (TTM)
GelirUS$31.47m
Gelir MaliyetiUS$102.78m
Brüt Kâr-US$71.31m
Diğer GiderlerUS$69.18m
Kazançlar-US$140.49m

Son Raporlanan Kazançlar

Sep 30, 2024

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)-2.55
Brüt Marj-226.64%
Net Kâr Marjı-446.49%
Borç/Özkaynak Oranı-141.4%

MRNS uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

Şirket Analizi ve Finansal Veri Durumu

VeriSon Güncelleme (UTC saati)
Şirket Analizi2025/02/10 07:05
Gün Sonu Hisse Fiyatı2025/02/07 00:00
Kazançlar2024/09/30
Yıllık Kazançlar2023/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

PaketVeriZaman ÇerçevesiÖrnek ABD Kaynağı *
Şirket Finansalları10 yıl
  • Gelir tablosu
  • Nakit akış tablosu
  • Bilanço
Analist Konsensüs Tahminleri+3 yıl
  • Finansal tahminler
  • Analist fiyat hedefleri
Piyasa Fiyatları30 yıl
  • Hisse senedi fiyatları
  • Temettüler, Bölünmeler ve Eylemler
Sahiplik10 yıl
  • En büyük hissedarlar
  • İçeriden öğrenenlerin ticareti
Yönetim10 yıl
  • Liderlik ekibi
  • Yönetim Kurulu
Önemli Gelişmeler10 yıl
  • Şirket duyuruları

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına Github sayfamızdan ulaşabilirsiniz; ayrıca raporlarımızı nasıl kullanacağınıza dair kılavuzlarımız ve YouTube’da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Marinus Pharmaceuticals, Inc. 7 Bu analistlerden 7, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

AnalistKurum
Kimberly LeeBrean Capital Historical (Janney Montgomery)
François BriseboisCraig-Hallum Capital Group LLC
Douglas TsaoH.C. Wainwright & Co.